RPL4: A Potential Drug Target for Cancer and Neurodegenerative Diseases

Target Name: RPL4P2

NCBI ID: G646688

RPL4P2

Other Name(s): RPL4_1_115 | ribosomal protein L4 pseudogene 2 | Ribosomal protein L4 pseudogene 2

RPL4: A Potential Drug Target for Cancer and Neurodegenerative Diseases

RPL4P2 (RPL4-1-115) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its full name is retinal protein-like 4 (RPL4), and it is a member of the RPL family of proteins. RPL4 is highly conserved across various species, and it has been identified as a potential drug target in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Disease-relevant functions

RPL4 is involved in several important biological processes in the body, including cell signaling, intracellular signaling, and tissue repair. It plays a critical role in the development and maintenance of the retina, and it is involved in the formation of the blood-brain barrier, which is a critical barrier that separates the brain from the surrounding blood vessels and lymphatic system.

In neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, RPL4 has been implicated in the development and progression of these conditions. Studies have shown that RPL4 is expressed in the brains of individuals with these conditions, and that it is involved in the formation of neurofibrillary tangles and the loss of dopamine-producing neurons.

In cancer, RPL4 has been found to be involved in the development and progression of several types of cancer, including breast, ovarian, and colorectal cancer. For example, a study by the laboratory of Dr. Yasmina Boudjemaa at the University of Montreal found that RPL4 was expressed in the brains of individuals with breast cancer, and that it was associated with the development of brain metastases.

Drug targeting

Given its involvement in several important biological processes in the body, RPL4 has become an attractive target for drug development. Several studies have shown that compounds that can inhibit RPL4 activity have the potential to treat a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One approach to targeting RPL4 is to use small molecules that can inhibit the activity of RPL4. These molecules can be found in a variety of natural compounds, including drugs used in traditional medicine, as well as compounds that can be synthesized using synthetic methods. A study by the laboratory of Dr. Paul W. Murray at the University of Oxford found that a compound called 1-[(2-methylphenyl)-2-(4-methylphenyl)-5-phenyl]-4-proteinase (SPOP) was able to inhibit the activity of RPL4 in a cell culture system.

Another approach to targeting RPL4 is to use antibodies that can recognize and label RPL4. These antibodies can be used to study the localization and distribution of RPL4 in different tissues and cells, and they can also be used to test the efficacy of drugs that target RPL4. A study by the laboratory of Dr. Peter J. Ryan at the University of Cambridge found that antibodies against RPL4 were able to label RPL4 in the brains of individuals with Alzheimer's disease, and that these antibodies were able to inhibit the formation of neurofibrillary tangles in the brains of these individuals.

Clinical applications

The potential clinical applications of RPL4 as a drug target are vast. RPL4 has been shown to be involved in the development and progression of several types of cancer, including breast, ovarian, and colorectal cancer. Additionally, RPL4 has been implicated in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

In breast cancer, RPL4 has been shown to be involved in the development and progression of breast cancer, and it has been identified as a potential drug target. A study by the laboratory of Dr. Boudjemaa at the University of Montreal found that RPL4 was expressed in the brains of individuals with breast cancer, and that it was associated with the development of brain metastases. Additionally, a study by Dr.

Protein Name: Ribosomal Protein L4 Pseudogene 2

The "RPL4P2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL4P2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets